Kadowaki I, Ichinohasama R, Sasaki O, Kimura J, Kameoka J I, Meguro K, Endo K, Tobinai K, Sasaki T, Sawai T, Ooya K
Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Leuk Lymphoma. 1998 Oct;31(3-4):393-403. doi: 10.3109/10428199809059233.
Although three subtypes of non-Hodgkin's lymphoma (NHL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL), are now well recognized as independent categories, their biological behavior has not been fully compared. One of the reasons for this may be that subclassification by histological examination alone is often difficult since they all have a common variant of a "nodular" growth pattern and occasionally show similar cytological morphology. Recently, we reviewed patients with FL, MCL and MZL, who were prospectively diagnosed, using multiparameter analyses with unfixed fresh biopsy materials. Of 407 NHL patients, 101 (24.8%) belonged to these three categories and 80 could be followed; FL (n=27), MCL (n=27) and MZL (n=26). Twenty eight cases with diffuse large B-cell (DL-B) lineage lymphoma were selected as control at random. The frequency of the MCL patients with performance status (PS) 2 to 4 (41%) was significantly higher than MZL patients (4%) [P< 0.001]. The 3 year survival rate with FL, MCL, MZL and DL-B was 71.5%, 57.4%, 93.3% and 53.1%, respectively. The survival rate for MZL was significantly better than both FL (p = 0.048) and MCL (p = 0.0085). Significant differences were also found in the overall survival rates among the four risk groups as defined by the International Index [I2](low, low-intermediate, high-intermediate and high; 97.4%, 79.6%, 39.4% and 18.2%, respectively). A multivariate analysis revealed that the International Index may be a significant predictor for short survival (p=0.0001) in the patients with FL, MCL or MZL. These results suggest that MZL shows an apparently better prognosis than FL and MCL and is found to be a prognostically independent category. In contrast, the clinical outcome in MCL is the worst among the three subtypes and was closer to that of DL-B. The International Index can be applied to a wide spectrum of NHL, including MCL, MZL and FL, to and can predict prognosis in these cases.
尽管非霍奇金淋巴瘤(NHL)的三种亚型,即滤泡性淋巴瘤(FL)、套细胞淋巴瘤(MCL)和边缘区淋巴瘤(MZL),现已被公认为独立的类别,但其生物学行为尚未得到充分比较。造成这种情况的原因之一可能是,仅通过组织学检查进行亚分类往往很困难,因为它们都有“结节状”生长模式的常见变体,且偶尔显示出相似的细胞学形态。最近,我们回顾了使用未固定新鲜活检材料进行多参数分析前瞻性诊断的FL、MCL和MZL患者。在407例NHL患者中,101例(24.8%)属于这三个类别,80例可进行随访;FL(n = 27)、MCL(n = 27)和MZL(n = 26)。随机选择28例弥漫性大B细胞(DL - B)谱系淋巴瘤患者作为对照。MCL患者中表现状态(PS)为2至4的频率(41%)显著高于MZL患者(4%)[P < 0.001]。FL、MCL、MZL和DL - B的3年生存率分别为71.5%、57.4%、93.3%和53.1%。MZL的生存率显著优于FL(p = 0.048)和MCL(p = 0.0085)。在国际预后指数[I2]定义的四个风险组(低、低中、高中和高;分别为97.4%、79.6%、39.4%和18.2%)的总生存率中也发现了显著差异。多变量分析显示,国际预后指数可能是FL、MCL或MZL患者短期生存的重要预测指标(p = 0.0001)。这些结果表明,MZL的预后明显优于FL和MCL,是一个预后独立的类别。相比之下,MCL的临床结果在这三种亚型中最差,与DL - B更接近。国际预后指数可应用于包括MCL、MZL和FL在内的广泛NHL,并可预测这些病例的预后。